Company overview
Aptamer Group develops Optimer synthetic binders, next-generation aptamers for life sciences and pharma applications including biomarker discovery, targeted drug delivery, and therapeutics. Their proprietary platforms enable custom aptamer selection for targets from small molecules to proteins, supporting drug discovery, diagnostics, and gene therapy delivery. Services are offered via fee-for-service models, integrating Optimer technology with proteomic analysis for high-throughput biomarker identification.
Aptamer Group is listed in the NovaPharmaNews Supplier Hub as a Diagnostics & Testing partner serving United States & Americas. Core focus areas include aptamers, optimer binders, biomarker discovery, targeted drug delivery, gene therapy, pharma r&d.
Industry categories: Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://aptamergroup.com
- Categories
- Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- aptamers, optimer binders, biomarker discovery, targeted drug delivery, gene therapy, pharma r&d, synthetic binders
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What are Optimer binders and their key applications in pharma?
- Optimer binders are proprietary next-generation synthetic aptamers used throughout drug discovery for biomarker discovery, targeted therapeutics, gene therapy delivery, and blood-brain barrier crossing. They serve as agonists, antagonists, or targeting moieties with high specificity and chemical modifiability.
- What capabilities does Aptamer Group's biomarker discovery service offer?
- The service combines Optimer technology with proteomic analysis for unbiased, high-throughput identification of disease biomarkers, providing validated markers and affinity ligands. It supports diagnostic development, therapeutic monitoring, and resistance marker identification via fee-for-service without internal infrastructure needs.
- What target types and discovery methods does Aptamer Group support?
- Aptamer Group offers multiple discovery processes for targets ranging from small molecules to proteins, peptides, and oligonucleotides. Methods can run in parallel or combined for rapid custom aptamer development in research, diagnostics, and therapeutics.
Related editorial coverage
- FDA CBER Patient Listening Meeting on Gene Therapy Safety: Patient and Care Partner Perspectives
- Sensorion pivots to SENS-601 after Regeneron’s OTOF hearing loss advance
- $2M Gene Therapy Cures Need a Financing Model
- Gene Therapy FDA Approval for Rare Disease: Updated List and Analysis
- Exclusive: FDA issues industry-friendly gene therapy guidance: What BD teams need to know
- FDA Issues June 2026 Guidance: Gene Therapy, Payor Comms, and CMC Flexibilities
Explore lab tools and QA/QC resources for R&D teams.
